시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 혈전증 및 지혈 바이오마커 시장 보고서(2025년)
Thrombosis And Hemostasis Biomarkers Global Market Report 2025
상품코드 : 1769774
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 혈전증 및 지혈 바이오마커 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 이 성장 예측에 기여하는 요인으로는 뇌졸중이나 허혈성 이벤트의 급증, 정맥 혈전 색전증에 대한 의식의 높아짐, 혈우병 등의 출혈성 질환의 이환율 증가, 외과적 개입 증가, 헬스케어 예산의 확대 등을 들 수 있습니다. 예측 기간 중에 예상되는 주목할만한 동향으로는 바이오마커 검출 기술의 진보, D 다이머와 피브리노겐의 초고감도 측정법의 개발, POC(Point of Care) 진단 툴의 대두, 바이오 마커의 해석과 예측을 위한 인공지능 통합, 임상시험 검사 자동화 진전 등이 있습니다.

정밀 및 표적 치료에 대한 수요 증가가 향후 몇 년간의 혈전증 및 지혈 바이오마커 시장의 성장을 견인할 것으로 예측됩니다. 이러한 치료법은 환자의 질환의 분자적 및 유전적 특징에 초점을 맞추어, 부작용을 최소한으로 억제하면서 효능의 향상을 목표로 하는 선진적인 치료 어프로치입니다. 수요 증가는 질병의 유전적 및 분자적 변이에 대한 이해가 깊어짐에 기인하고 있어, 이것에 의해 맞춤형 치료가 가능하게 되어, 치료 성적의 향상과 리스크의 저감이 실현됩니다.

혈전증 및 지혈 바이오마커 시장의 각사는 출혈성 질환 검사의 정밀도와 신뢰성을 향상시키기 위해 자동 VWF 활성 측정법 등의 첨단 진단 솔루션의 개발을 점점 추진하고 있습니다. 자동 VWF 활성 측정법은 면역비탁법이나 화학발광법과 같은 기술을 이용하여 지혈에 관여하는 중요한 당단백질인 폰 빌레브란트 인자(VWF)와 혈소판 당단백질 Ib의 결합 효율을 평가하는 고처리량 검사입니다. 이것은 폰 빌레브란트 질병의 진단과 모니터링에 필수적입니다. 예를 들어, 2022년 10월 독일에 본사를 둔 의료 기술 기업인 Siemens Healthineers는 VWF 활성 측정의 정확성을 높이기 위해 설계된 완전 자동 검사인 INNOVANCE VWF Ac 측정법을 발표했습니다. VWF GPIbM 기술을 활용한 이 측정법은 혈소판 결합 활성을 직접 평가하여 기존 방법보다 감도와 정밀도가 향상되었습니다. VWF는 출혈과 혈전증 모두와 관련된 바이오마커로 널리 알려져 있기 때문에 이 새로운 측정법은 이전에 검출할 수 없었던 VWF 변이체의 확인에 도움이 되어 폰 빌레브란트 병의 진단 능력을 향상시킵니다. 게다가 이 측정법은 미국 혈액학회(ASH), 국제혈전지혈학회(ISTH), 전미혈우병재단(NHF)의 최신 임상 가이드라인에 부합하며 최신 진단법의 중요성을 강조하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

Thrombosis and hemostasis biomarkers are biological indicators that offer valuable insights into the mechanisms of blood clot formation and the regulation of bleeding. These biomarkers play a vital role in monitoring the equilibrium between clot development and its breakdown, serving as essential tools in evaluating vascular health and diagnosing coagulation-related disorders.

The primary products in the thrombosis and hemostasis biomarkers market include reagents and consumables as well as analyzers. Reagents and consumables encompass crucial chemical agents and disposable lab supplies-such as assay kits, buffers, calibrators, and control solutions-used for detecting, measuring, and analyzing biomarkers associated with clotting and bleeding conditions. These products are utilized in a variety of diagnostic tests, including D-dimer, anti-thrombin III, plasminogen, soluble fibrin, factor VIII, prothrombin (PT), activated partial thromboplastin time (APTT), and others. Their applications span across cardiovascular diseases, neurological disorders, cancer, pregnancy-related complications, and orthopedic surgeries. Key end users of these biomarkers include hospitals, diagnostic laboratories, pharmaceutical firms, academic research centers, and home healthcare providers.

The thrombosis and hemostasis biomarkers market size has grown strongly in recent years. It will grow from $4.80 billion in 2024 to $5.17 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. Growth during the historical period was driven by factors such as a rise in cardiovascular disease prevalence, an aging population, an increase in cancer-related thrombosis, a surge in obesity and sedentary behavior, as well as the growing burden of diabetes and metabolic disorders.

The thrombosis and hemostasis biomarkers market size is expected to see strong growth in the next few years. It will grow to $6.87 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. Factors fueling this projected growth include a surge in cases of stroke and ischemic events, heightened awareness of venous thromboembolism, an increased incidence of bleeding disorders like hemophilia, a growing number of surgical interventions, and expanding healthcare budgets. Notable trends anticipated during the forecast period include advancements in biomarker detection technologies, the development of ultra-sensitive assays for D-dimer and fibrinogen, the rise of point-of-care diagnostic tools, the integration of artificial intelligence for biomarker interpretation and forecasting, and increased automation in clinical laboratory testing.

The increasing demand for precise and targeted therapies is anticipated to drive the growth of the thrombosis and hemostasis biomarkers market in the coming years. These therapies are advanced treatment approaches that focus on the molecular and genetic characteristics of a patient's disease, aiming to improve efficacy while minimizing side effects. The rise in demand stems from a deeper understanding of genetic and molecular variations in diseases, which allows for more individualized treatment, thereby enhancing therapeutic outcomes and reducing risks. This trend supports the thrombosis and hemostasis biomarkers market by facilitating the development of more accurate diagnostic tools that can identify specific biomarkers, leading to more effective and tailored treatments for clotting disorders. For example, in March 2024, Novotech, an Australia-based contract research organization (CRO), reported that 43% of the 217 FDA-approved oncology therapies by the end of 2023 are categorized as precision oncology treatments, with 78 of them incorporating DNA or Next Generation Sequencing (NGS)-detectable biomarkers. As a result, the growing demand for these targeted therapies is expected to fuel market expansion.

Companies in the thrombosis and hemostasis biomarkers market are increasingly developing advanced diagnostic solutions such as automated VWF activity assays to improve the accuracy and reliability of bleeding disorder testing. An automated VWF activity assay is a high-throughput laboratory test that employs techniques like immunoturbidimetry or chemiluminescence to evaluate the binding efficiency of von Willebrand factor (VWF)-a key glycoprotein involved in hemostasis-to platelet glycoprotein Ib. This is essential for diagnosing and monitoring von Willebrand disease. For instance, in October 2022, Siemens Healthineers, a Germany-based medical technology company, introduced the INNOVANCE VWF Ac assay, a fully automated test designed to enhance the precision of VWF activity measurement. Utilizing VWF:GPIbM technology, this assay directly evaluates platelet binding activity and offers improved sensitivity and accuracy over earlier methods. As VWF is a widely recognized biomarker associated with both bleeding and thrombosis, the new assay helps in identifying previously undetectable VWF variants, thus enhancing diagnostic capabilities for von Willebrand disease. Moreover, it aligns with the latest clinical guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Hemostasis (ISTH), and the National Hemophilia Foundation (NHF), underscoring its importance in modern diagnostic practices.

In February 2024, Procuritas Capital Investors, a Sweden-based private equity firm, acquired Precision BioLogic (PBI) and Affinity Biologicals for an undisclosed amount. This strategic acquisition aims to strengthen Procuritas' presence in the growing thrombosis and hemostasis diagnostics market. Precision BioLogic, based in Canada, offers FDA-cleared reagents and plasma-based products, along with strong research and development capabilities. Affinity Biologicals, also based in Canada, specializes in manufacturing products used in thrombosis and hemostasis research and diagnostics, including custom assay services. The deal is expected to leverage the strengths of both companies to capitalize on global healthcare trends and expand Procuritas' diagnostic portfolio.

Major players in the thrombosis and hemostasis biomarkers market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton, Dickinson and Company (BD), Mayo Clinic Laboratories, bioMerieux S.A., Beckman Coulter Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., Cincinnati Children's Hospital Medical Center, ARUP Laboratories, HORIBA Ltd., Werfen S.A., Pathkind Diagnostics Pvt. Ltd., Diagnostica Stago, Agilus Diagnostics, Helena Laboratories Corporations, Cleveland Clinic Laboratories, Diazyme Laboratories Inc., Biomedica Diagnostics Inc., Atlas Medical GmbH.

North America was the largest region in the thrombosis and hemostasis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thrombosis and hemostasis biomarkers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the thrombosis and hemostasis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The thrombosis and hemostasis biomarkers market consists of revenues earned by entities by providing services such as clinical laboratory testing services, patient risk assessment services, disease monitoring services, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombosis and hemostasis biomarkers market also includes sales of clot waveform analysis kits, microfluidic coagulation testing devices, and factor assay kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Thrombosis And Hemostasis Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on thrombosis and hemostasis biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for thrombosis and hemostasis biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The thrombosis and hemostasis biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Thrombosis And Hemostasis Biomarkers Market Characteristics

3. Thrombosis And Hemostasis Biomarkers Market Trends And Strategies

4. Thrombosis And Hemostasis Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Thrombosis And Hemostasis Biomarkers Growth Analysis And Strategic Analysis Framework

6. Thrombosis And Hemostasis Biomarkers Market Segmentation

7. Thrombosis And Hemostasis Biomarkers Market Regional And Country Analysis

8. Asia-Pacific Thrombosis And Hemostasis Biomarkers Market

9. China Thrombosis And Hemostasis Biomarkers Market

10. India Thrombosis And Hemostasis Biomarkers Market

11. Japan Thrombosis And Hemostasis Biomarkers Market

12. Australia Thrombosis And Hemostasis Biomarkers Market

13. Indonesia Thrombosis And Hemostasis Biomarkers Market

14. South Korea Thrombosis And Hemostasis Biomarkers Market

15. Western Europe Thrombosis And Hemostasis Biomarkers Market

16. UK Thrombosis And Hemostasis Biomarkers Market

17. Germany Thrombosis And Hemostasis Biomarkers Market

18. France Thrombosis And Hemostasis Biomarkers Market

19. Italy Thrombosis And Hemostasis Biomarkers Market

20. Spain Thrombosis And Hemostasis Biomarkers Market

21. Eastern Europe Thrombosis And Hemostasis Biomarkers Market

22. Russia Thrombosis And Hemostasis Biomarkers Market

23. North America Thrombosis And Hemostasis Biomarkers Market

24. USA Thrombosis And Hemostasis Biomarkers Market

25. Canada Thrombosis And Hemostasis Biomarkers Market

26. South America Thrombosis And Hemostasis Biomarkers Market

27. Brazil Thrombosis And Hemostasis Biomarkers Market

28. Middle East Thrombosis And Hemostasis Biomarkers Market

29. Africa Thrombosis And Hemostasis Biomarkers Market

30. Thrombosis And Hemostasis Biomarkers Market Competitive Landscape And Company Profiles

31. Thrombosis And Hemostasis Biomarkers Market Other Major And Innovative Companies

32. Global Thrombosis And Hemostasis Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Thrombosis And Hemostasis Biomarkers Market

34. Recent Developments In The Thrombosis And Hemostasis Biomarkers Market

35. Thrombosis And Hemostasis Biomarkers Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기